Linking to the development of economic growth with digital financial inclusion and supply chain management in China.

Much research demonstrates the positive effects of financial inclusion and digital finance on expansion. Supply chains that can be relied upon are essential to national productivity and economic development. This study uses panel data from 2007 to 2022 covering 27 provinces in China to study the results of widespread access to digital financial services and supply chain management on regional economic growth using the instrumental variable approach (fixed effect model). In contrast to earlier research, this study employs an alternative measure of access to digital financial services utilization and digitalization. The data demonstrates that digital financial inclusion and supply chain management have a major impact on the development of the provincial economies in China. Based on the results of this research, we suggest increasing digital financial inclusion and bolstering human capital development to stimulate economic expansion. This essay makes a theoretical advancement in studying digital technology's widespread adoption of financial services by providing a comprehensive critical review and a fresh angle on the nuts and bolts of digital money and universal banking. Boosting institutional quality and governance are two more paths that authorities can take to stimulate economic expansion in the China area, and the results show how important these measures are for achieving this goal.

Paclitaxel and carboplatin combined with antiangiogenesis therapy for patients with metastatic mucosal malignant melanoma / 肿瘤

Objective: To observe the efficacy and safety of paclitaxel and carboplatin combined with antiangiogenesis therapy in patients with metastatic mucosal melanoma. Methods: Paclitaxel (175 mg/m2 d1) and carboplatin [area under the curve (AUC) = 5 mL/min d1] combined with recombinant human endostar (15 mg/d d1-14) or bevacizumab (5 mg/kg d1, d15) were administrated to 46 patients with metastatic mucosal melanoma, which had been confirmed by histopathology. The regimen was repeated every 28 days and would continue until the patients achieved progression or had untolerated side effects. The response and toxicity were evaluated after the end of each cycle. All patients were followedup. The progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The number of cycles given was 1-6 (mean: 3.7±1.1). Among 46 evaluable cases, one case achieved complete response, three achieved partial response, 23 achieved stable disease, and tumor progression was seen in 19 cases. The objective response rate was 8.7% (4/46) and the clinical benefit rate was 58.7% (27/46). The median PFS reached 3.0 months [95% confidence interval (CI ): 1.7-4.3] and the median OS reached 10.0 months (95% CI : 7.3-12.7). Mutivariate analysis revealed that, as compared with the patients with normal serum lactate dehydrogenase (LDH) level, the patients with elevated serum LDH level had a better OS [hazard ratio: 0.436 (95% CI : 0.193-0.985); P = 0.046]. The main grade 3/4 toxicity was myelosuppression, including neutropenia (n = 12, 26.1%) and thrombocytopenia (n = 2, 4.3%); the rate of grade 3/4 peripheral neuropathy was 10.9% (5/46). Conclusion: Paclitaxel and carboplatin combined with antiangiogenesis therapy for patients with metastatic mucosal melanoma can achieve clinical benifit and it is well tolerated. More clinical trials should be needed to comfirm the efficacy of this regimen.